| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CTSL1 |
| Uniprot No | P07711 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 114-288 |
| 氨基酸序列 | APRSVDW REKGYVTPVK NQGQCGSCWA FSATGALEGQ MFRKTGRLIS LSEQNLVDCS GPQGNEGCNG GLMDYAFQYV QDNGGLDSEE SYPYEATEES CKYNPKYSVA NDTGFVDIPK QEKALMKAVA TVGPISVAID AGHESFLFYK EGIYFEPDCS SEDMDHGVLV VGYGFEST |
| 预测分子量 | 37,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是假设的3篇关于CTSL1重组蛋白的参考文献示例，供参考：
---
1. **文献名称**: *"Expression and Functional Characterization of Recombinant Human CTSL1 in HEK293 Cells"*
**作者**: Zhang, Y. et al.
**摘要**: 研究报道了在HEK293哺乳动物细胞中成功表达重组人源CTSL1蛋白，并通过亲和层析纯化获得高活性酶。实验验证了重组CTSL1的底物特异性及最适pH条件，为肿瘤微环境中的蛋白酶功能研究提供工具。
---
2. **文献名称**: *"Structural Insights into CTSL1 Protease Activity via Crystallographic Analysis of Recombinant Protein"*
**作者**: Müller, R. & Schmidt, B.
**摘要**: 通过X射线晶体学解析了重组CTSL1的三维结构，揭示了其催化活性位点的关键氨基酸残基及与抑制剂结合的分子机制，为设计靶向CTSL1的抗癌药物奠定基础。
---
3. **文献名称**: *"Recombinant CTSL1 as a Novel Biomarker for Inflammatory Diseases"*
**作者**: Li, X. et al.
**摘要**: 研究利用重组CTSL1蛋白开发了特异性抗体，并发现其在类风湿关节炎患者的血清中显著高表达，提示CTSL1可能作为炎症性疾病的潜在诊断标志物。
---
(注：以上文献为模拟内容，实际引用需核实真实出版物。)
Cathepsin L1 (CTSL1) is a lysosomal cysteine protease belonging to the papain-like protease family. It plays critical roles in intracellular protein degradation, antigen processing, and extracellular matrix remodeling. The enzyme is synthesized as an inactive pro-enzyme that undergoes proteolytic cleavage in acidic environments to become active. CTSL1 exhibits broad substrate specificity, targeting proteins such as collagen, elastin, and hormones, making it essential for tissue homeostasis, cellular proliferation, and apoptosis regulation.
Recombinant CTSL1 protein is produced using genetic engineering techniques, typically by inserting the human CTSL1 gene into expression systems like Escherichia coli, mammalian cells (e.g., HEK293 or CHO), or insect cells. Post-translation modifications, such as glycosylation, are preserved in eukaryotic systems to ensure functional activity. The recombinant protein is purified via affinity chromatography, often utilizing tags like His-tag for efficient isolation.
Research applications of recombinant CTSL1 include studying its involvement in pathological processes, including cancer metastasis, viral entry (e.g., SARS-CoV-2), and neurodegenerative diseases. It serves as a tool for drug discovery, particularly in developing protease inhibitors. Additionally, CTSL1's role in antigen presentation links it to autoimmune and inflammatory diseases, highlighting its therapeutic targeting potential. Dysregulation of CTSL1 has been associated with tumor progression, making it a biomarker candidate for certain cancers. Its recombinant form enables mechanistic studies and high-throughput screening for therapeutic agents, bridging basic research and clinical applications.
×
